Tadalafil Tablet, Film Coated
Product Images NDC 50090-8047

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 50090-8047). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500908047)

Tadalafil 20 mg film-coated tablets label from A-S Medication Solutions. The label indicates each film-coated tablet contains 20 mg of Tadalafil USP. It includes storage instructions to keep between 68 to 77 degrees Fahrenheit and a package count of 30 tablets. The product NDC is 50090-8047-0.*

FDA Label Image

Spl-tadalafil-figure-1 (Spl Tadalafil Figure 1)

A set of four line graphs showing differences in blood pressure measurements (systolic and diastolic) over time (hours) comparing Tadalafil to placebo. The panels depict Standing Systolic BP, Standing Diastolic BP, Supine Systolic BP, and Supine Diastolic BP, with differences in mmHg plotted on the vertical axis and time in hours on the horizontal axis.*

FDA Label Image

Spl-tadalafil-figure-2 (Spl Tadalafil Figure 2)

A dual line graph depicting changes in standing and supine systolic blood pressure (mmHg) over 24 hours post-dose. Two treatments are compared: Tadalafil 20 mg with doxazosin 8 mg (solid line) and placebo with doxazosin 8 mg (dotted line). The y-axis measures blood pressure change from baseline, while the x-axis shows time in hours after dosing.*

FDA Label Image

Spl-tadalafil-figure-3 (Spl Tadalafil Figure 3)

A line graph showing the effect on systolic blood pressure (mmHg) over 12 hours after administration of 20 mg tadalafil or placebo combined with 8 mg doxazosin at 08:00 and 20:00. The graph includes four data series comparing blood pressure changes for tadalafil and placebo given at morning and evening doses.*

FDA Label Image

Spl-tadalafil-figure-4 (Spl Tadalafil Figure 4)

A line graph depicting plasma tadalafil concentration (µg/L) over time (hours) for three dosing scenarios: single 20-mg tadalafil dose, single 5-mg tadalafil dose, and once-daily 5-mg tadalafil following 5 consecutive days of administration. The graph shows concentration peaks, decline, and error bars for variability across the 0 to 120-hour timeframe.*

FDA Label Image

Spl-tadalafil-figure-5 (Spl Tadalafil Figure 5)

A line graph comparing the change from baseline in IPSS total score over 12 weeks of treatment between Tadalafil 5 mg and placebo. The x-axis shows duration of treatment in weeks (0, 4, 8, 12), and the y-axis shows change in IPSS total score. The Tadalafil group shows a greater decrease in scores over time compared to placebo, with a statistically significant difference noted at 12 weeks (p<0.01).*

FDA Label Image

Spl-tadalafil-figure-6 (Spl Tadalafil Figure 6)

Line graph depicting the change from baseline in IPSS total score over 12 weeks of treatment, comparing Tadalafil 5 mg (solid line with circles) and placebo (dashed line with triangles). The x-axis represents treatment duration in weeks, and the y-axis shows the change in scores. Significant differences (p<0.01) are marked at weeks 4 and 12 for Tadalafil.*

FDA Label Image

Spl-tadalafil-figure-8 (Spl Tadalafil Figure 8)

A line graph comparing the change from baseline in IPSS total score over 12 weeks between Tadalafil 5 mg and placebo. The y-axis shows change from baseline, and the x-axis represents treatment duration in weeks. The Tadalafil group shows a greater decrease in score over time compared to placebo, with statistical significance indicated at 12 weeks.*

FDA Label Image

Spl-tadalafil-structure (Spl Tadalafil Structure)

Chemical structure of Tadalafil, showing the molecular arrangement of atoms including rings, nitrogen, oxygen, and methyl groups, consistent with the generic compound used in the Tadalafil 20 mg film-coated tablet by A-S Medication Solutions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.